Search

Displaying results 6881 - 6890 of 9714 in total
  1. Drug

    Etozoline

    go.drugbank.com/drugs/DB08982
    Experimental

    Etozoline is a loop diuretic.

  2. Drug

    Etofibrate

    go.drugbank.com/drugs/DB08983
    Experimental

    Etofibrate is a fibrate produced by the combination of clofibrate ester linked to niacin.

  3. Drug

    Etamivan

    go.drugbank.com/drugs/DB08989
    ApprovedWithdrawn

    Etamvin is a respiratory stimulant drug similar to nikethamide. It is no longer used in the United States.

  4. Drug

    Ditazole

    go.drugbank.com/drugs/DB08994
    ApprovedWithdrawn

    Additionally, ditazole is a platelet aggregation inhibitor marketed in Spain and Portugal with trade name Ageroplas. … Ditazole is a non-steroidal anti-inflammatory drug (NSAID). Ditazole's analgesic and antipyretic effects are similar to phenylbutazone.

  5. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    Barbexaclone, a salt compound of propylhexedrine and phenobarbital, is a potent antiepileptic. By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. … These reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials.

  6. Drug

    Clocapramine

    go.drugbank.com/drugs/DB09003
    Experimental

    Clocapramine has been implicated in at least one strange death, including a suicide.

  7. Drug

    Beclamide

    go.drugbank.com/drugs/DB09011
    Experimental

    Beclamide (N-benzyl-B-chloropropionamide) is a no longer used drug that possesses anticonvulsant and sedative activity.

  8. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct

  9. Drug

    Netupitant

    go.drugbank.com/drugs/DB09048
    ApprovedInvestigational

    Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.

  10. Drug

    Elosulfase alfa

    go.drugbank.com/drugs/DB09051
    ApprovedInvestigational

    The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week. … Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome.